Development and Clinical Effectiveness of Antiandrogens in the Treatment of Advanced Prostate Cancer

Medical Council
doi 10.21518/2079-701x-2016-10-34-37
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Heterogeneity of Advanced Prostate Cancer: Clinical Implications of Genomics

Trends in Urology & Men's Health
2017English

Clinical and Economic Analysis of Effectiveness of Everolimus in the Treatment of HR+, HER2- Advanced Breast Cancer in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Looking Beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer

Advances in Andrology
2014English

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer

Clinical Medicine Insights: Urology
2013English

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

Simultaneous Administration of Pure Antiandrogens, a Combination Necessary for the Use of Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Prostate Cancer.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1984English

Vinflunine in the Treatment of Advanced Urothelial Cancer: Clinical Evidence and Experience

Therapeutic Advances in Urology
Urology
2016English

Long-Term Clinical Results of IGRT in Prostate Cancer Treatment

Klinicka Onkologie
Oncology
2020English

Cost-Effectiveness Analysis of LHRH Agonists in the Treatment of Metastatic Prostate Cancer in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy